In Suspected Fetal Growth Restriction, <scp>sFlt</scp> ‐1/ <scp>PlGF</scp> and <scp>PlGF</scp> May Have Value in Risk Stratification for Preterm Birth and Birthweight < 3rd Centile: A Blinded Cohort Study
We investigated the value of measuring sFlt-1/PlGF in people with suspected fetal growth restriction (sFGR) without signs of preeclampsia at recruitment. Angiogenic biomarkers were considered positive when sFlt-1/PlGF > 38 or PlGF < 100 pg/mL. Clinicians were blinded to the sFlt-1/PlGF results. In sFGR presenting < 32 weeks, but not ≥ 32-37 weeks, positive angiogenic biomarkers vs. NZ FGR criteria had increased risk of preterm birth RR 5.32 [2.04-13.88] vs. 2.19 [0.89-5.37], respectively, and birthweight < 3rd centile RR 2.11 [1.24-3.58] vs. 1.83 [0.92-3.63], respectively. Larger studies are needed to establish whether routine testing of angiogenic biomarkers in sFGR is recommended for risk stratification.
Authors
- Joanna Gullam
- Ruth Hughes (ORCID: https://orcid.org/0000-0002-9181-7934)
- Ian Phillips
- Pippa Kyle
- Chris Florkowski
Institutions
- Christchurch Hospital (NZ)
- Canterbury Health Laboratories (NZ)
- University of Otago (NZ)
Publication Details
- Journal
- Australian and New Zealand Journal of Obstetrics and Gynaecology
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1111/ajo.70003
- Citations
- 2
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 4.11
Funders
- University of Otago